Paper Details

  1. Home
  2. Paper Details

Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.

Author: HarrowerA D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Gliclazide, a sulphonylurea, demonstrated efficacy in managing diet-failed noninsulin-dependent diabetes mellitus (NIDDM) patients. In three studies, gliclazide achieved good glycaemic control in 65% of patients, compared favorably with other sulphonylureas, and had a low incidence of side effects.
Paper Details　
Original Abstract of the Article :
Three studies were performed to assess the efficacy of various sulphonylureas in the management of diet-failed NIDDM patients. In the first study, 224 patients inadequately controlled by diet alone or with oral hypoglycaemics received gliclazide in addition to diet or in place of existing drugs for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0168-8227(91)90010-b

データ提供：米国国立医学図書館（NLM）

Gliclazide: A Powerful Weapon in the Battle Against NIDDM

This study explores the effectiveness of gliclazide, a sulfonylurea drug, in managing patients with non-insulin-dependent diabetes mellitus (NIDDM), a condition characterized by impaired insulin production and utilization. The researchers conducted multiple studies to compare gliclazide with other sulfonylurea drugs, evaluating its efficacy in controlling blood sugar levels. Think of NIDDM as a desert where the body's ability to use water effectively is compromised, leading to imbalances and health problems. Gliclazide, like a well-timed oasis, helps restore the body's ability to manage blood sugar levels, improving overall health and well-being.

Gliclazide: A Promising Oasis in the Desert of Diabetes

The study showcases the potential of gliclazide to effectively manage NIDDM, offering a promising alternative to other sulfonylurea drugs. It's like discovering a new oasis in the desert of diabetes, providing a source of relief and effective management for individuals struggling with this condition. The study's findings encourage the use of gliclazide as a valuable treatment option for NIDDM, potentially improving glycemic control and enhancing long-term health outcomes.

Managing NIDDM: A Journey Through the Desert of Glucose

This study reminds us of the importance of managing NIDDM effectively, emphasizing the need for appropriate medications and lifestyle changes. It's like navigating a vast desert, where understanding the terrain and taking necessary precautions is essential for survival. The study's findings encourage a multi-faceted approach to managing NIDDM, including medication, dietary changes, and regular exercise.

Dr. Camel's Conclusion

This study highlights the effectiveness of gliclazide in managing non-insulin-dependent diabetes mellitus (NIDDM), a condition that can often feel like navigating a desert of glucose imbalances. The study's findings offer a glimmer of hope for individuals struggling with NIDDM, reminding us that effective treatment options exist. The research encourages continued research into the management of diabetes, ensuring that individuals have access to the best possible care and support.
Date :
  1. Date Completed 1992-04-06
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

1794268

DOI: Digital Object Identifier

10.1016/0168-8227(91)90010-b

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.